At 12.6% CAGR, the North America Aortic Valve Replacement Devices Market is Projected to be Worth US$ 8,603.28 million by 2030, says The Business Market Insights

According to the Business Market Insights’ research, the North America aortic valve replacement devices market was valued at US$ 3,333.33 million in 2022 and is expected to reach US$ 8,603.28 million by 2030, registering a CAGR of 12.6% from 2022 to 2030. Rising number of aortic valve replacement surgeries and increasing demand for minimally invasive techniques are among the critical factors attributed to the North America aortic valve replacement devices market expansion.                     

A surge in research activity is driven by several factors, including growing prevalence of aortic valve diseases, advancements in medical technology, and need for more evidence-based approaches to treatment. Clinical studies are crucial in assessing the safety and efficacy of new surgical techniques, prosthetic valves, and transcatheter interventions. These studies also help identify risk factors, optimize patient selection criteria, and evaluate long-term outcomes to improve patient care and quality of life. As the demand for aortic valve replacement continues to rise, so does the importance of conducting robust clinical trials to provide healthcare professionals and patients with the best available evidence for making informed treatment options. With ongoing research and collaboration between medical institutions, the future of aortic valve replacement looks promising, with the potential for even more innovative and effective approaches on the horizon.

A few technological advancements by the players in the aortic valve replacement devices are mentioned below:

•          Trial started in January 2019, innovative device for pain management by millimeter band radiation: electronic-pain killer (EPIKARD).

Trial started in January 2017, vascular closure device in transcatheter aortic valve replacement. Evaluation of the safety and efficacy of a percutaneous plug-based large-bore vascular closure device for femoral artery closure in an unselected consecutive patient cohort undergoing transcatheter aortic valve implantation in a single-center prospective study.  

On the contrary, product recalls hurdle the growth of North America aortic valve replacement devices market.

Based on product, the North America aortic valve replacement devices market is segmented into sutureless valve and mechanical valve. The sutureless valve segment held 61.0% share of North America aortic valve replacement devices market in 2022, amassing US$ 2,033.02 million. It is projected to garner US$ 5,431.64 million by 2030 to expand at 13.1% CAGR during 2022–2030.

Based on surgery, the North America aortic valve replacement devices market is segmented into minimally invasive surgery and open surgery. The minimally invasive surgery segment held 87.1% share of North America aortic valve replacement devices in 2022, amassing US$ 2,904.88 million. It is projected to garner US$ 7,748.76 million by 2030 to expand at 13.0% CAGR during 2022–2030.  

Based on end user, the North America aortic valve replacement devices market is segmented into hospitals & clinics, ambulatory surgical centers, and others. The hospitals & clinics segment held 67.6% share of North America aortic valve replacement devices market in 2022, amassing US$ 2,251.80 million. It is projected to garner US$ 5,992.74 million by 2030 to expand at 13.0% CAGR during 2022–2030.

Based on country, the North America aortic valve replacement devices market has been categorized into the US, Canada, and Mexico.  Our regional analysis states that the US captured 85.4% share of North America aortic valve replacement devices market in 2022. It was assessed at US$ 2,847.00 million in 2022 and is likely to hit US$ 7,492.60 million by 2030, exhibiting a CAGR of 12.9% during 2022–2030.      

Key players operating in the North America aortic valve replacement devices market are Abbott Laboratories; Artivion Inc; Boston Scientific Corp; Braile Biomedica Industry, Commerce and Representations Ltd; Edwards Lifesciences Corp; LivaNova Plc; Medtronic Plc; JenaValve Technology Inc; and Venus MedTech HangZhou Inc, among others.   

• In May 2023, Edwards Lifesciences announced new data from the COMMENCE aortic trial, demonstrating low structural valve deterioration (SVD) rates in bioprosthetic aortic valves with the company's innovative RESILIA tissue. The data, representing the longest clinical follow-up for Edwards' bioprosthetic surgical aortic valve with RESILIA tissue with a mean follow-up of 7.7 years, were presented at the 103rd annual meeting of the American Association for Thoracic Surgery.    
• In Feb 2023, Medtronic relaunched its Harmony Transcatheter Pulmonary Valve (TPV) System, a minimally invasive alternative to open-heart surgery for congenital heart disease patients with native or surgically repaired right ventricular outflow tract (RVOT).

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com